Cingulate therapeutics filing
WebCingulate Inc. Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation ... WebAmendment to Employment Agreement, effective April 1, 2024, between Cingulate Therapeutics LLC and Raul R. Silva; Cingulate Inc. Reports First Quarter 2024 Results …
Cingulate therapeutics filing
Did you know?
WebUncategorized (1) Contracts. Master Services Agreement between Cingulate Therapeutics LLC and Societal CDMO, Inc., dated October 24, 2024 (Filed With SEC on October 25, 2024) Promissory Note, dated August 9, 2024, between Cingulate Therapeutics, LLC and Werth Family Investment Associates LLC (Filed With SEC on August 11, 2024) … WebJun 29, 2024 · The most recently filed 13Fs
WebApr 11, 2024 · On April 04, 2024, Cingulate Inc. (NASDAQ: CING) announced it had completed the first cohort of its Phase 3 adult onset and duration trial of its lead candidate, CTx-1301 (dexmethylphenidate), for attention deficit/hyperactivity disorder (ADHD). The Phase 3 CTx-1301-022 study (NCT05631626) assesses the onset and duration of CTx … WebDec 8, 2024 · Cingulate Inc. is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to …
WebThe Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. ... Cingulate Therapeutics: Street Address 1 Street Address 2; 6 SOUTH STREET: SUITE 203: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; MORRISTOWN: NEW … WebMar 10, 2024 · Inside Cingulate Inc.'s 10-K Annual Report: Financial - Expense Highlight. We have experienced, and will continue to experience, increased expenses associated …
WebSep 14, 2024 · Cingulate, Inc. ( NASDAQ: CING) is a clinical-stage biopharmaceutical company with a proprietary Precision Timed Release (PTR) drug delivery platform …
WebSep 9, 2024 · Cingulate Inc. S-1 Filing information. Filed on 9 September 2024 SEC Edgar 000149315221022284 Exhibits & attachments & exports. ... Top menu > File > Make a copy... Copy & paste the following URL into the D2 cell: Do you need help with the setup? Let us know at [email protected]. Close. china shelleyWebCingulate Therapeutics is a Biotechnology, Pharmaceuticals, and Pharmaceutical Manufacturing company located in Morristown, New Jersey with $2.00 Million in revenue and 14 employees. Find top employees, contact details and business statistics at RocketReach. ... (28 currently) – along with the filing of multiple provisional applications ... china shell porcelain sinksWebApr 6, 2024 · Cingulate's stock was trading at $1.00 at the beginning of the year. Since then, CING stock has decreased by 3.8% and is now trading at $0.9619. View the best growth stocks for 2024 here. china shell measuring spoonsWebCingulate General Information. Description. Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery … china shelley englandWebJul 11, 2024 · About Cingulate Therapeutics ... Cingulate anticipates filing INDs for both assets in the third and fourth quarters of 2024 and will pursue approval via the accelerated 505(b)(2) regulatory ... china shelves using pipeWebMay 31, 2024 · Cingulate anticipates filing INDs for CTX-1301 and CTX-1302 via the accelerated 505 (b)(2) regulatory pathway. The company has offices in Kansas City, KS and Morristown, NJ. For more information ... grammarly yearly planWebOct 13, 2024 · Cingulate Therapeutics' IPO date and price. Cingulate is expected to start trading on Oct. 15. The company now plans to raise $40 million by offering 4.4 million … grammarly yearly fee